BEXSERO (Meningococcal Group B Vaccine) is an FDA-approved vaccine to help protect against meningitis B. Learn more about meningitis B vaccination.
It is not known whether the vaccine components of BEXSERO are excreted in human milk. Available data are not sufficient to assess the effects of BEXSERO on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with ...
The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the ...
Side effects Dosage information During pregnancy FDA approval history Drug class: bacterial vaccines Patient resources Bexsero drug information Professional resources Meningococcal Group B Vaccine monograph Other brands Trumenba Related treatment guides Meningitis, Meningococcal Meningococcal Disease ProphylaxisMedic...
Serogroup B is the only major disease-associated capsular group of Neisseria meningitidis for which no protein-polysaccharide conjugate vaccine is available. This has led to the development of multi-component protein-based vaccines that target serogroup B invasive meningococcal disease (IMD), including ...